Optic Neuritis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 58 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Optic Neuritis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Optic Neuritis - Pipeline Review, H2 2014', provides an overview of the Optic Neuritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Optic Neuritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Optic Neuritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Optic Neuritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Optic Neuritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Optic Neuritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Optic Neuritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Optic Neuritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Optic Neuritis Overview 6
Therapeutics Development 7
Pipeline Products for Optic Neuritis - Overview 7
Pipeline Products for Optic Neuritis - Comparative Analysis 8
Optic Neuritis - Therapeutics under Development by Companies 9
Optic Neuritis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Optic Neuritis - Products under Development by Companies 13
Optic Neuritis - Companies Involved in Therapeutics Development 14
Biogen Idec Inc. 14
Bionure Farma, S.L. 15
Mallinckrodt plc 16
Meta-IQ ApS 17
Mitsubishi Tanabe Pharma Corporation 18
Neuralstem, Inc. 19
Teijin Pharma Limited 20
Optic Neuritis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
BIIB-033 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BN-201 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
corticotropin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
etomoxir - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
fingolimod hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
immune globulin (human) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NSI-566 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Optic Neuritis - Recent Pipeline Updates 43
Optic Neuritis - Dormant Projects 55
Optic Neuritis - Discontinued Products 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
Number of Products under Development for Optic Neuritis, H2 2014 7
Number of Products under Development for Optic Neuritis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Optic Neuritis - Pipeline by Biogen Idec Inc., H2 2014 14
Optic Neuritis - Pipeline by Bionure Farma, S.L., H2 2014 15
Optic Neuritis - Pipeline by Mallinckrodt plc, H2 2014 16
Optic Neuritis - Pipeline by Meta-IQ ApS, H2 2014 17
Optic Neuritis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 18
Optic Neuritis - Pipeline by Neuralstem, Inc., H2 2014 19
Optic Neuritis - Pipeline by Teijin Pharma Limited, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Optic Neuritis Therapeutics - Recent Pipeline Updates, H2 2014 43
Optic Neuritis - Dormant Projects, H2 2014 55
Optic Neuritis - Discontinued Products, H2 2014 56